Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Concomitant MEK and Cyclin Gene Alterations: Implications for Response to Targeted Therapeutics.

Clinical cancer research : an official journal of the American Association for Cancer Research - 15 May 2021

Kato Shumei, Adashek Jacob J, Shaya Justin, Okamura Ryosuke, Jimenez Rebecca E, Lee Suzanna, Sicklick Jason K, Kurzrock Razelle

Abstract excerpt

PURPOSE: Cyclin and MAPK/MEK-related gene alterations are implicated in cell-cycle progression and cancer growth. Yet, monotherapy to target the cyclin (CDK4/6) or the MEK pathway has often yielded disappointing results. Because coalterations in cyclin and MEK pathway genes frequently cooccur, we hypothesized that resistance to CDK4/6 or MEK inhibitor monotherapy might be mediated via activation of oncogenic...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biomarkers, Tumor
Share to Cyclins

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Disease Susceptibility

Share to Mitogen-Activated Protein Kinase Kinases

Share to Molecular Targeted Therapy

Share to Neoplasm Staging

Share to Protein Kinase Inhibitors

Share to Tomography, X-Ray Computed

Source

Open in PubMed Open full text

Identifiers

PMID: 33472910
DOI: 10.1158/1078-0432.CCR-20-3761
PMCID: PMC11005753

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Concomitant MEK and Cyclin Gene Alterations: Implications for Response to Targeted Therapeutics.PMID 33472910Read ↗

Cyclin alterations in diverse cancers: Outcome and co-amplification network.Semantic proximity Read ↗

Cyclin Pathway Genomic Alterations Across 190,247 Solid Tumors: Leveraging Large-Scale Data to Inform Therapeutic Directions.Semantic proximity Read ↗

Targeting RAS Mutant Colorectal Cancer with Dual Inhibition of MEK and CDK4/6.Semantic proximity Read ↗

Separable cell cycle arrest and immune response elicited through pharmacological CDK4/6 and MEK inhibition in RASmut disease modelsSemantic proximity Read ↗

CDK4/6 inhibitors have potent activity in combination with pathway selective therapeutic agents in models of pancreatic cancerSemantic proximity Read ↗

Targeting CDK1 and MEK/ERK Overcomes Apoptotic Resistance in BRAF-Mutant Human Colorectal Cancer.Semantic proximity Read ↗

Co-targeting BRAF and cyclin dependent kinases 4/6 for BRAF mutant cancers.Semantic proximity Read ↗

Transcriptional Antagonism by CDK8 Inhibition Improves Therapeutic Efficacy of MEK Inhibitors.Semantic proximity Read ↗

Cyclin-dependent kinase pathway aberrations in diverse malignancies: clinical and molecular characteristicsSemantic proximity Read ↗

Comparative biomarker analysis of PALOMA-2/3 trials for palbociclibSemantic proximity Read ↗

Investigational drugs targeting cyclin-dependent kinases for the treatment of cancer: an update on recent findings (2013-2016)Semantic proximity Read ↗

MAPK Reliance via Acquired CDK4/6 Inhibitor Resistance in CancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.